Evidence map›Paper›PMID 41764610›Full record

ReviewMini reviews in medicinal chemistry2026

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.

Sushmita Bhatia, Neha Bhatia, Suresh Thareja

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sushmita BhatiaDepartment of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, Punjab 151401, India.
Neha BhatiaDepartment of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, Punjab 151401, India.
Suresh TharejaDepartment of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda, Punjab 151401, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inavolisib is a selective phosphoinositide 3-kinase alpha (PI3Kα) inhibitor representing the next generation of anticancer drugs for the treatment of PIK3CA-mutated HR+/HER2- breast cancer. The dysregulated PI3K/AKT/mTOR signalling axis is an established mechanism of breast cancer progression and resistance to therapy, emphasizing the need for selective inhibitors that have both improved tolerance and efficacy. Inavolisib exhibits enhanced potency and selectivity for PI3Kα, resulting in superior antitumor activity and lower off-target effects than older generations of PI3K inhibitors. The present review provides a comprehensive discussion on inavolisib, covering its structure, pharmacokinetic properties, mechanism of action, and in vivo preclinical efficacy. The antitumor effects of combination strategies are also being highlighted for their potential to overcome endocrine resistance and optimize patient outcomes. Furthermore, it discusses the emerging resistance mechanisms to PI3K inhibition, mitigation of adverse effects, and future directions for inavolisib in personalized oncology. As studies continue to demonstrate its clinical utility, inavolisib exhibits preferential activity against the mutated PI3Kα isoform, thereby enhancing therapeutic specificity for combination therapy.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsAnimalsErb-b2 Receptor Tyrosine KinasesFemaleHumansImidazolesMutationOxazepinesOxazoles2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamideAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImidazolesinavolisibOxazepinesOxazolesPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanProtein Kinase Inhibitorsendocrine resistancefulvestrantInavolisibpalbociclibpharmacokineticsPI3Kα inhibitortargeted therapy

Identifiers

PMID41764610

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.